



For immediate distribution  
Source: DIAGNOS Inc.

**2016.04.07**

## **DIAGNOS Announces Private Placement**

Brossard, Quebec, Canada – April 7, 2016 - DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces a private placement (“Private Placement”) of up to \$1,070,000 worth of units (each a “Unit”). Each Unit consists of:

- One Secured Convertible Debenture (“Debenture”), \$10,000 principal amount, 1-Year Term, 12% Annual Interest, and
- 50,000 Stock Warrants (each a “Warrant”) entitling the holder to purchase one Common Share (“Share”) per Warrant at a price of \$0.06 per Share for a period of one year from the date of issuance.

At the sole option of the holders of the Debentures, the principal amount of the Debentures may be converted at any time, in whole or in part, into common shares of the Corporation at a price of \$0.06 per common share. Any accrued interest on the principal, at time of conversion, is immediately payable in cash.

There will be no cash proceeds as the Debentures and Warrants will be issued solely in settlement of outstanding debt pertaining to Unsecured Convertible and Redeemable Promissory Notes (“Notes”), bearing interest at 10%, with a conversion and redemption price of \$0.16, issued between March 31, 2014 and May 2, 2014.

The Corporation has retained the services of Dundee Goodman Private Wealth, a division of Dundee Securities Ltd. (“Dundee”), to act as a referral agent in connection with the Private Placement. As per the engagement agreement, Dundee is entitled to receive a commission in cash of 4% on the value of Debentures issued to subscribers referred by Dundee.

The Debentures will be sold in Canada on a prospectus-exempt basis and the Shares underlying the Debentures and Warrants will be subject to a statutory four-month hold period from the closing date.

This proposed Private Placement is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the negotiation and execution of formal documentation.

Closing of the Private Placement is expected to take place on, or around, May 2nd, 2016 (“Closing Date”). Within 10 days after the Closing Date, the Corporation shall make a special payment, in the form of interests at the annual rate of 12%, to compensate the holders of the Debentures and Warrants for the number of accrued days between the date of issuance of the Debentures and Warrants and the expiry date of the initial Notes.

All monies quoted in this press release shall be stated and paid in lawful money of Canada.

### About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission to improve the quality of patients’ lives and minimize the economic burden of vision loss. Computer Assisted Retinal Analysis (CARA) is the Company’s proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a



TSXV: ADK

*For immediate distribution*  
Source: DIAGNOS Inc.

cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, the U.S. Food and Drug Administration, and the European Union.

Forward-looking information

This document contains forward-looking information that involves risks and uncertainties, including without limitation, statements pertaining to the Private Placement and its use of proceeds. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. Unless required under law, DIAGNOS will not update this forward-looking information to reflect new events or circumstances

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

André Larente, President, DIAGNOS  
Telephone: 1-877-678-8882 or (450) 678-8882, ext.: 224